Phase I/II Trial of STAR15 Combination Therapy for Metastatic Colorectal Cancer
A Phase I/II study is underway to evaluate a combination of four experimental therapies for metastatic colorectal cancer.
Asset / Drug
Drug and asset intelligence for retifanlimab with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
June 28, 2026 · N/A
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.